热门资讯> 正文
投资组合更新后C4 Therapeutics上涨
2025-01-15 03:02
- Shares of C4 Therapeutics (NASDAQ:CCCC) traded higher on Tuesday after the cancer drug developer highlighted its upcoming milestones and updated its 2024 financials.
- Notable events expected from the Watertown, Massachusetts-based biotech include the completion of Phase 1 dose escalation for the company’s lead candidate, cemsidomide, in multiple myeloma, with its data anticipated for an H2 2025 release.
- Phase 1 dose escalation for cemsidomide in non-Hodgkin’s lymphoma is also expected to conclude with a data readout set for an H2 2025 release.
- Other notable catalysts include the completion of Phase 1 dose escalation for CFT1946 against solid tumors, including colorectal cancer (CRC) and other carcinomas with V600 mutations. Data from those trials are expected in H2 2025.
- As for financials, C4 Therapeutics (NASDAQ:CCCC) projected a cash runway through 2027, citing its cash, cash equivalents, and marketable securities at the end of 2024.
More on C4 Therapeutics
- C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
- Seeking Alpha’s Quant Rating on C4 Therapeutics
- Historical earnings data for C4 Therapeutics
- Financial information for C4 Therapeutics
推荐文章
一周IPO丨双登股份下周上市，超额认购逾3000倍；佳鑫国际资源火热招股中
一周财经日历 | 超重磅！英伟达、阿里、拼多多财报轮番；美国7月PCE数据来袭
美股机会日报 | 倒计时开始！市场屏息以待鲍威尔讲话；中概股名创优品涨超8%，拼多多涨超4%
AH股追踪丨上证指数一举突破3800点！中芯国际A股飙涨14%，H股涨逾9%
港股异动 | 中兴通讯H股午后持续拉升！盘中涨超13%创历史新高
华盛早报 | 韩国股民疯买港股，外资传大消息，做多中国热情持续攀升；标普“五连阴”！今晚华尔街枕戈以待
美股机会日报 | 关税税率最高15%！美欧敲定框架贸易协议；何小鹏增持310万股，小鹏汽车盘前股价涨超5%
一图看懂 | 哔哩哔哩Q2营收73亿元！上半年手游收入大增68%，经调净利润同比扭亏为盈5.6亿元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
